Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC6 | Q9Y210 | 15/20 | 0.73 |
| ▸ | TRPC3 | Q13507 | 14/20 | 0.73 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23068148 | 0.92 | TRPC6 (0.74) | TRPC6TRPC3TRPC7AR | |
| SCHEMBL29025006 | 0.90 | TRPC6 (0.66) | TRPC6TRPC3TRPC7 | |
| SCHEMBL23068102 | 0.85 | TRPC3 (0.72) | TRPC6TRPC3USP30 | |
| SCHEMBL21550529 | 0.85 | TRPC6 (1.00) | TRPC6TRPC3TRPC7 | |
| SCHEMBL23068128 | 0.85 | TRPC6 (1.00) | TRPC6TRPC3TRPC7 | |
| SCHEMBL29025025 | 0.82 | TRPC6 (0.68) | TRPC6TRPC3TRPC7DPP4 | |
| SCHEMBL14471465 | 0.80 | TRPC6 (0.72) | TRPC6TRPC3TRPC7 | |
| SCHEMBL14471464 | 0.80 | TRPC6 (0.72) | TRPC6TRPC3TRPC7 | |
| SCHEMBL30355226 | 0.77 | TRPC3 (0.72) | TRPC6TRPC3 | |
| SCHEMBL21550534 | 0.76 | TRPC6 (1.00) | TRPC6TRPC3TRPC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790870-B1 | CYCLOPENTANE COMPOUNDS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-04-19 | — | — | EP | disclosed |
| US-20220194922-A1 | CYCLOPENTANE COMPOUNDS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2022-06-23 | — | — | US | disclosed |
| US-20210070733-A1 | CYCLOPENTANE COMPOUNDS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194922-A1 | CYCLOPENTANE COMPOUNDS | CYP11B2, CYP11B1, SQLE | TRPC6 3706/4885TRPC3 3056/4885TRPC7 3651/4885 |
| US-20210070733-A1 | CYCLOPENTANE COMPOUNDS | CYP11B2, CYP11B1, CYP51A1 | TRPC6 3415/4885TRPC3 2969/4885TRPC7 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.